Reyon Pharmaceutical Co Ltd banner
R

Reyon Pharmaceutical Co Ltd
KRX:102460

Watchlist Manager
Reyon Pharmaceutical Co Ltd
KRX:102460
Watchlist
Price: 10 110 KRW 0.3% Market Closed
Market Cap: ₩187.9B

Intrinsic Value

The intrinsic value for Reyon Pharmaceutical Co Ltd (102460) under the Base Case is 10 127.28 KRW. Compared with the current market price of 10 110 KRW, the stock appears Fairly Valued .

Intrinsic value calculated using DCF
₩10 127.28
Other reference points

Do our valuations actually work? See backtest results .

Intrinsic Value
10 127.28
Fairly Valued
Intrinsic Value
Price ₩10 110
R
Monitor Reyon Pharmaceutical Co Ltd
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value ₩8 101.83
Get notified when the price drops into your buy zone
Intrinsic Value ₩10 127.28
Current Price ₩10 110
Margin of Safety 20% ₩8 101.83
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Ask AI Assistant
What other research platforms think about Reyon Pharmaceutical Co Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Reyon Pharmaceutical Co Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Reyon Pharmaceutical Co Ltd.

Explain Valuation
Alternatives to Reyon Pharmaceutical Co Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one Reyon Pharmaceutical Co Ltd stock?

The intrinsic value for Reyon Pharmaceutical Co Ltd (102460) under the Base Case is 10 127.28 KRW.

Is Reyon Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared with the current market price of 10 110 KRW, the stock appears Fairly Valued .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett